Ready for 2022?
17/09/20 -"Merck confirmed our positive view on the company. As expected, management confirmed the FY 2022 guidance and put some nice colour on 2021. The virtual Investors Day’s main topics gave helpful ..."
Pages
73
Language
English
Published on
17/09/20
You may also be interested by these reports :
21/11/25
Ever since Sandoz demerged from Novartis, the generics/biosimilars giant has been delivering on its promises, and remains well on track to achieve ...
19/11/25
AstraZeneca has been beating the street’s estimates over the last few quarters, on the back of strong growth momentum for its oncology, rare disease, ...
18/11/25
Over past eighteen months, there has been a glaring performance divergence for family-owned Ipsen (BUY; France) vs. AV Small Pharmas. While the ...
17/11/25
Our 2025 estimates have been revised significantly, following a substantial guidance upgrade during Q3 results, driven by stronger-than-expected ...